Disease-free survival · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in disease‐free survival ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Pathological complete response · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in pathological complete response (no invasive cancer in breast or… compared with anthracyclines followed by taxane (high certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).
1 finding from 1 review
Treatment adherence (defined as dose reduction) ( · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose reduction) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Quality of life · neoadjuvant therapy for early breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · adjuvant therapy for early breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease-free survival · adjuvant therapy for early breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to treatment failure (any reason related to treatment) All participants Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) All participants Range of compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) Subgroup: focal onset… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) ‐ stratified by epilepsy type: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) Subgroup: generalised… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Remission · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Metastasis · People undergoing radiotherapy for uterine cervical cancer
Hyperbaric oxygen showed no clear difference in metastasis compared with air breathing (high certainty).
1 finding from 1 review
Quality of life ‐ not reported · People undergoing radiotherapy for uterine cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · People undergoing radiotherapy for uterine cervical cancer
Hyperbaric oxygen leads to higher adverse effects compared with air breathing (high certainty).
1 finding from 1 review